Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs
VKTX Viking Therapeutics	$26.28 -0.6%	$26.82	$18.92 ▼ $81.73	$2.95B	0.65	4.05 million shs	2.28 million shs
VRNA Verona Pharma PLC American Depositary Share	$90.92 -2.2%	$73.95	$14.14 ▼ $94.45	$7.74B	0.21	1.32 million shs	1.01 million shs
ZLAB Zai Lab	$36.93 -0.8%	$32.70	$16.01 ▼ $44.34	$4.07B	0.96	902,163 shs	670,174 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
VKTX Viking Therapeutics	0.00%	-8.05%	-8.34%	-9.22%	-48.10%
VRNA Verona Pharma PLC American Depositary Share	0.00%	-1.71%	+21.66%	+36.09%	+486.58%
ZLAB Zai Lab	0.00%	-14.18%	+13.18%	+5.24%	+96.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	4.4288 of 5 stars	4.5	1.0	0.0	4.7	2.3	3.3	0.0
VRNA Verona Pharma PLC American Depositary Share	1.901 of 5 stars	2.5	3.0	0.0	0.0	2.0	2.5	0.6
ZLAB Zai Lab	2.0393 of 5 stars	3.4	1.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
TRIL Trillium Therapeutics	0.00	N/A	N/A	N/A
VKTX Viking Therapeutics	3.00	Buy	$87.15	231.64% Upside
VRNA Verona Pharma PLC American Depositary Share	3.00	Buy	$91.11	0.21% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	28.26% Upside

Current Analyst Ratings Breakdown

Latest TRIL, VRNA, ZLAB, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	VRNA Verona Pharma PLC American Depositary Share	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$92.00 ➝ $116.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$95.00 ➝ $110.00
6/2/2025	VRNA Verona Pharma PLC American Depositary Share	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $90.00
4/30/2025	VRNA Verona Pharma PLC American Depositary Share	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$93.00 ➝ $107.00
4/30/2025	VRNA Verona Pharma PLC American Depositary Share	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $85.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VRNA Verona Pharma PLC American Depositary Share	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/28/2025	VRNA Verona Pharma PLC American Depositary Share	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$100.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A
VRNA Verona Pharma PLC American Depositary Share	$42.28M	183.07	N/A	N/A	$2.56 per share	35.52
ZLAB Zai Lab	$398.99M	10.21	N/A	N/A	$7.68 per share	4.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,030.67	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/5/2025 (Estimated)

Latest TRIL, VRNA, ZLAB, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
TRIL Trillium Therapeutics	N/A	19.82	19.82
VKTX Viking Therapeutics	N/A	44.25	44.25
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
TRIL Trillium Therapeutics	87.15%
VKTX Viking Therapeutics	76.03%
VRNA Verona Pharma PLC American Depositary Share	85.88%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
TRIL Trillium Therapeutics	9.10%
VKTX Viking Therapeutics	4.10%
VRNA Verona Pharma PLC American Depositary Share	4.80%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable
ZLAB Zai Lab	1,869	110.33 million	104.86 million	Optionable

TRIL, VRNA, ZLAB, and VKTX Headlines

Recent News About These Companies

Mission Wealth Management LP Buys Shares of 20,000 Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 18 at 4:14 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why

June 17 at 12:43 PM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) versus Antibe Therapeutics (OTCMKTS:ATBPD) Head to Head Comparison

June 17 at 2:25 AM | americanbankingnews.com

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

June 13, 2025 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Time to Buy?

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Zai Lab FY2026 Earnings

June 11, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sets New 1-Year High - Here's What Happened

June 10, 2025 | marketbeat.com

Two Sigma Investments LP Trims Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 8, 2025 | marketbeat.com

Yajing Chen Sells 9,618 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

June 5, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $288,540.00 in Stock

June 5, 2025 | insidertrades.com

Bank of America Corp DE Has $1.63 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 5, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

June 4, 2025 | marketbeat.com

Squarepoint Ops LLC Acquires Shares of 27,961 Zai Lab Limited (NASDAQ:ZLAB)

June 3, 2025 | marketbeat.com

Legacy Wealth Asset Management LLC Buys Shares of 22,285 Zai Lab Limited (NASDAQ:ZLAB)

June 2, 2025 | marketbeat.com

Millennium Management LLC Sells 15,023 Shares of Zai Lab Limited (NASDAQ:ZLAB)

June 1, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) Sees Large Drop in Short Interest

June 1, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial

May 31, 2025 | insidermonkey.com

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025 | businesswire.com

Zai Lab Announces Participation in Investor Conferences in June 2025

May 30, 2025 | businesswire.com

Northern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB)

May 29, 2025 | marketbeat.com

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 28, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Renaissance Hedge Fund’s Biggest Q1 Buys Revealed
By Leo Miller | May 22, 2025
View Renaissance Hedge Fund’s Biggest Q1 Buys Revealed

TRIL, VRNA, ZLAB, and VKTX Company Descriptions

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Viking Therapeutics NASDAQ:VKTX

$26.28 -0.15 (-0.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$26.32 +0.04 (+0.15%)

As of 06/18/2025 07:56 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$90.92 -2.01 (-2.16%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$91.06 +0.14 (+0.15%)

As of 06/18/2025 07:14 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Zai Lab NASDAQ:ZLAB

$36.93 -0.29 (-0.78%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$36.91 -0.02 (-0.05%)

As of 06/18/2025 06:56 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time